A5072977882- 3D Printing in Biomedical Research
- Innovative Microfluidic and Catalytic Techniques Innovation
- Inhalation and Respiratory Drug Delivery
- SARS-CoV-2 and COVID-19 Research
- Cell Image Analysis Techniques
- Biosensors and Analytical Detection
- Respiratory viral infections research
- Asthma and respiratory diseases
- SARS-CoV-2 detection and testing
- Respiratory Support and Mechanisms
Draper Laboratory
2021-2024
Influenza and other respiratory viruses present a significant threat to public health, national security, the world economy, can lead emergence of global pandemics such as from COVID-19. A barrier development effective therapeutics is absence robust predictive preclinical model, with most studies relying on combination in vitro screening immortalized cell lines low-throughput animal models. Here, we integrate human primary airway epithelial cells into custom-engineered 96-device platform...
Microphysiological organ-on-chip models offer the potential to improve prediction of drug safety and efficacy through recapitulation human physiological responses. The importance including multiple cell types within tissue has been well documented. However, study interactions in vitro can be limited by complexity model throughput current culture systems. Here, we describe development a co-culture microvascular relevant assays high-throughput thermoplastic platform, PREDICT96. system consists...
COVID-19 emerged as a worldwide pandemic in early 2020, and while the rapid development of safe efficacious vaccines stands an extraordinary achievement, identification effective therapeutics has been less successful. This process limited part by lack human-relevant preclinical models compatible with therapeutic screening on native virus, which requires high-containment environment. Here, we report SARS-CoV-2 infection robust viral replication PREDICT96-ALI, high-throughput, human primary...
Abstract Despite the relatively common observation of therapeutic efficacy in discovery screens with immortalized cell lines, vast majority drug candidates do not reach clinical development. Candidates that move forward often fail to demonstrate when progressed from animal models humans. This dilemma highlights need for new screening technologies can parse early development regard predicted relevance use. PREDICT96-ALI is a high-throughput organ-on-chip platform incorporating human primary...
Abstract COVID-19 emerged as a worldwide pandemic early in 2020, and at this writing has caused over 170 million cases 3.7 deaths worldwide, almost 600,000 the United States. The rapid development of several safe highly efficacious vaccines stands one most extraordinary achievements modern medicine, but identification administration therapeutics to treat patients suffering from been far less successful. A major factor limiting progress effective treatments lack suitable preclinical models...
Abstract The average cost to bring a new drug from its initial discovery patient's bedside is estimated surpass $2 billion and requires over decade of research development. There need for screening technologies that can parse candidates with increased likelihood clinical utility early in development order increase the cost‐effectiveness this pipeline. For example, during COVID‐19 pandemic, resources were rapidly mobilized identify effective therapeutic treatments but many lead antiviral...